Advertisement

Topics

Novartis erhält Zulassung in EU für Krebsmittel-Biosimilar Rixathon

01:52 EDT 19 Jun 2017 | FinanzNachrichten

Basel/Holzkirchen (awp) - Die Generika-Tochter von Novartis, Sandoz, hat für ihr Biosimilar Rixathon (Rituximab) in der EU die Zulassung erhalten. Wie aus einer Medienmitteilung vom Montag hervorge...

Original Article: Novartis erhält Zulassung in EU für Krebsmittel-Biosimilar Rixathon

NEXT ARTICLE

More From BioPortfolio on "Novartis erhält Zulassung in EU für Krebsmittel-Biosimilar Rixathon"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...